Inhye E. Ahn

2.9k total citations
69 papers, 1.2k citations indexed

About

Inhye E. Ahn is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Inhye E. Ahn has authored 69 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Genetics, 27 papers in Pathology and Forensic Medicine and 24 papers in Immunology. Recurrent topics in Inhye E. Ahn's work include Chronic Lymphocytic Leukemia Research (53 papers), Lymphoma Diagnosis and Treatment (27 papers) and Immunodeficiency and Autoimmune Disorders (21 papers). Inhye E. Ahn is often cited by papers focused on Chronic Lymphocytic Leukemia Research (53 papers), Lymphoma Diagnosis and Treatment (27 papers) and Immunodeficiency and Autoimmune Disorders (21 papers). Inhye E. Ahn collaborates with scholars based in United States, South Korea and Spain. Inhye E. Ahn's co-authors include Adrian Wiestner, Xin Tian, Mohammed Farooqui, Jennifer R. Brown, Susan Soto, Clare Sun, Jennifer Lotter, Pia Nierman, Juan Gea‐Banacloche and Sarah E. M. Herman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Inhye E. Ahn

61 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inhye E. Ahn United States 17 828 632 402 289 216 69 1.2k
Jun Takizawa Japan 18 263 0.3× 426 0.7× 340 0.8× 428 1.5× 191 0.9× 75 1.1k
Julia Hoellenriegel United States 10 900 1.1× 656 1.0× 421 1.0× 191 0.7× 466 2.2× 18 1.4k
Karla Plevová Czechia 18 451 0.5× 279 0.4× 519 1.3× 232 0.8× 651 3.0× 48 1.3k
Mitsufumi Nishio Japan 19 493 0.6× 265 0.4× 624 1.6× 264 0.9× 262 1.2× 38 1.3k
M Fitchett United Kingdom 19 841 1.0× 584 0.9× 471 1.2× 180 0.6× 503 2.3× 31 1.8k
Junichi Kiyasu Japan 16 313 0.4× 790 1.3× 438 1.1× 739 2.6× 99 0.5× 40 1.2k
Ilseung Choi Japan 22 221 0.3× 615 1.0× 935 2.3× 692 2.4× 213 1.0× 99 1.7k
Daniela Lens Uruguay 15 467 0.6× 397 0.6× 298 0.7× 246 0.9× 209 1.0× 40 898
Tony G. Willis United Kingdom 13 553 0.7× 890 1.4× 513 1.3× 526 1.8× 675 3.1× 17 1.8k
Jerry Z. Gong United States 7 354 0.4× 520 0.8× 192 0.5× 648 2.2× 298 1.4× 8 1.0k

Countries citing papers authored by Inhye E. Ahn

Since Specialization
Citations

This map shows the geographic impact of Inhye E. Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inhye E. Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inhye E. Ahn more than expected).

Fields of papers citing papers by Inhye E. Ahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inhye E. Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inhye E. Ahn. The network helps show where Inhye E. Ahn may publish in the future.

Co-authorship network of co-authors of Inhye E. Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of Inhye E. Ahn. A scholar is included among the top collaborators of Inhye E. Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inhye E. Ahn. Inhye E. Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lee, Jumi, et al.. (2025). Promiscuous enzyme SQOR in cellular metabolism and ferroptosis regulation. BMB Reports. 58(6). 233–237. 1 indexed citations
3.
4.
Ahn, Inhye E. & Matthew S. Davids. (2024). Therapeutic targeting of apoptosis in chronic lymphocytic leukemia. Seminars in Hematology. 61(2). 109–118. 4 indexed citations
5.
Woyach, Jennifer A., Paul M. Barr, Thomas J. Kipps, et al.. (2023). Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study. Cancers. 15(2). 507–507. 10 indexed citations
6.
Chen, Jonathan, Erika M. Gaglione, Chingiz Underbayev, et al.. (2023). CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy. Clinical Cancer Research. 29(18). 3612–3621. 11 indexed citations
7.
Gaglione, Erika M., John H. Herrick, Inhye E. Ahn, et al.. (2023). Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Advances. 7(15). 4089–4101. 27 indexed citations
8.
Woyach, Jennifer A., Paolo Ghia, John C. Byrd, et al.. (2023). B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clinical Cancer Research. 29(16). 3065–3073. 7 indexed citations
9.
Ahn, Inhye E., et al.. (2023). Prognostic Markers in the Era of Targeted Therapies. Acta Haematologica. 147(1). 33–46. 9 indexed citations
10.
Tedeschi, Alessandra, Inhye E. Ahn, Graeme Fraser, et al.. (2023). Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials. Hematological Oncology. 41(S2). 461–463.
11.
Davids, Matthew S., Kathleen A. Rogers, Nitin Jain, et al.. (2023). Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome. Hematological Oncology. 41(S2). 466–468. 11 indexed citations
12.
Baptista, Maria João, Sivasubramanian Baskar, Erika M. Gaglione, et al.. (2021). Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research. 27(16). 4624–4633. 8 indexed citations
13.
Brieghel, Christian, Michael Asger Andersen, Christina W. Yde, et al.. (2021). Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research. 27(16). 4531–4538. 24 indexed citations
14.
Ahn, Inhye E. & Jennifer R. Brown. (2021). Targeting Bruton’s Tyrosine Kinase in CLL. Frontiers in Immunology. 12. 687458–687458. 52 indexed citations
15.
Davids, Matthew S., Kirsten Fischer, Sandra Robrecht, et al.. (2021). ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 2634–2634. 8 indexed citations
16.
Ahn, Inhye E., Xin Tian, David Ipe, et al.. (2020). Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. Journal of Clinical Oncology. 39(6). 576–585. 56 indexed citations
17.
Sun, Clare, Camilia Soof, Sarah E. M. Herman, et al.. (2017). Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood. 130. 4031–4031. 2 indexed citations
18.
Wu, Shijie, Ruth M. Pfeiffer, Inhye E. Ahn, et al.. (2016). Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non- MMSET Myeloma Patients. Clinical Cancer Research. 22(16). 4039–4044. 12 indexed citations
19.
Ahn, Inhye E. & Sham Mailankody. (2016). Controversies in multiple myeloma: Evidence-based update. Seminars in Oncology. 43(6). 666–675. 4 indexed citations
20.
Ahn, Inhye E., Ji Hyeon Ju, Kwi Young Kang, Sung‐Hwan Park, & Ho‐Youn Kim. (2009). The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptor. Clinical Rheumatology. 29(2). 225–227. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Takizawa Breakdown of academic impact, for papers by Julia Hoellenriegel Breakdown of academic impact, for papers by Karla Plevová Breakdown of academic impact, for papers by Mitsufumi Nishio Breakdown of academic impact, for papers by M Fitchett Breakdown of academic impact, for papers by Junichi Kiyasu Breakdown of academic impact, for papers by Ilseung Choi Breakdown of academic impact, for papers by Daniela Lens Breakdown of academic impact, for papers by Tony G. Willis Breakdown of academic impact, for papers by Jerry Z. Gong
Rankless by CCL
2026